Stage 2: 15 evaluable subjects per cohort will be enrolled. An evaluable subject is one who has completed both SC infusions and has completed protocol-specified assessments sufficient for determination of safety and tolerability. Subjects not meeting these criteria, including those withdrawn prematurely for reasons other than toxicity, will be replaced. Enrollment of Cohort 3 is dependent on findings in Cohorts 1 and 2. Allowing for some non-evaluable subjects in up to three cohorts, each including 15 evaluable subjects, a total of up to 60 subjects may be entered in this Stage 2.